Advertisement
The increase was driven by the continued strong sales of its anti-cancerand other therapeutic treatments products, as well as increased demands fromEurope, Japan, Korea and India. This marks the tenth consecutive year ofdouble digit revenue growth.
Advertisement
"We delivered solid performance in 2009 and look forward to growing ourtop and bottom line in 2010," said Dr. Jo Shen, President and CEO ofScinoPharm. "Our performance is directly attributed to our core strategy offocusing on high value and high technological barrier products, which willfurther ScinoPharm's market leadership position in generic APIs," Dr. Shenadded.
2010 Outlook
ScinoPharm has several new API products for generic drugs scheduled forcommercialization in 2010, including products for breast cancer, prostatecancer, and ovarian cancer. In addition, two New Chemical Entity (NCE)projects are expected to get approval from FDA for commercial launch.
ScinoPharm has also accelerated its pace by developing cell lines and labprocesses for seven biosimilars. Among them are monoclonal antibodies used inthe treatment of cancer and rheumatoid arthritis. ScinoPharm also continues toexpand with the construction of a new production facility and a new R&D sitein Changshu, Jiangsu Province, scheduled to be completed in 2011.
About ScinoPharm Taiwan
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturingservice provider to the global pharmaceutical industry. With cGMP productionfacilities, ScinoPharm offers a wide portfolio of services ranging from customsynthesis for early phase pharmaceutical activities to brand companies as wellas APIs for the generic industry. Combining cost-effective resources andproductivity of Asia along with extensive regulatory know-how, ScinoPharm isuniquely positioned to serve global pharmaceutical R&D and manufacturing needsat any level and for any company in this sector. For more information pleasevisit http://www.scinopharm.com .Media Contact: ScinoPharm Taiwan, Ltd. Sabrian Wu TEL: +886-6-505-2869 Mobile: +886-920-056-385 Email: [email protected]
SOURCE ScinoPharm Taiwan, Ltd.
